Artículos científicos

Intraductal (IDC) and cribriform (CRIB) histologies in prostate cancer have been associated with germline BRCA2 (gBRCA2) mutations in small retrospective series, leading to the recommendation of genetic testing for patients with IDC in the primary tumour.

Autores: Rebeca Lozano, Daniela C. Salles, Shahneen Sandhu, Isabel M. Aragón, Heather Thorne, Fernando López-Campos, José Rubio-Briones, Ana M. Gutierrez-Pecharroman, Laneisha Maldonado, Tomas di Domenico, Alejandro Sanz, Juan D. Prieto, Isabel García, María I. Pacheco, Teresa Garcés, Casilda Llacer, Nuria Romero-Laorden, Francisco Zambrana, Pedro P. López-Casas, David Lorente, Joaquin Mateo, Colin C. Pritchard, Emmanuel S. Antonarakis, David Olmos, Tamara L. Lotan, Elena Castro.

Fuente: European Journal of Cancer, Volume 147, 2021, Pages 74-83, ISSN 0959-8049.

Secondary amyloidosis is a rare complex complication related to chronic inflammatory disease. This complication is sparsely associated to malignant neoplasms. Renal cell carcinoma (RCC) is the most common solid organ malignancy related with this paraneoplastic syndrome. Some case reports have described stabilisation or even remission of amyloidosis with cytoreductive nephrectomy. Majority of those reports were based on locally advanced RCC. We report the first case of early aggressive systemic secondary amyloidosis in high-volume metastatic RCC. The subject was diagnosed with metastatic RCC within 6 months of secondary amyloidosis; on month 5 of initiation of targeted therapy (pazopanib) developed nephrotic syndrome with a heavy proteinuria (>18 g/day), severe hypoalbuminaemia (1.53 g/dL), intense and progressive oedema, severe pancolitis and mild dyspnoea with hypotension. A colon biopsy and the immunohistochemistry confirmed the histological diagnosis of a secondary amyloidosis. The multidisciplinary tumour board decided to perform cytoreductive nephrectomy in order to reduce the pro-inflammatory status. Pathology report showed a complete resection of clear cell RCC plus renal amyloid deposits. The patient died within 4 days of surgery due to multiorgan failure.

Autores: Algarra Maria Asunción, Fita Maria José Juan, Sandiego Sergio, Aguilar Héctor Augusto, Álvarez Pablo, Quispe Mateo, Salvador Antonio, Egido Adoración, Lavernia Javier, Machado Isidro, Rubio Briones José, Climent Miguel Ángel.

Fuente: ecancer.org 14 1156

El objetivo del estudio consistió en describir los factores clínicos que llevan a los médicos a realizar pruebas de imagen para identificar metástasis en pacientes con cáncer de próstata (CP) resistente a la castración no metastásico (CPRCnm).

Autores: J.M. Cózar Olmo, J. Carballido Rodríguez, J. Rubio-Briones, E. Useros Rodríguez, J. Muñoz del Toro, Á. García García-Porrero, Á. Juárez-Soto.

Fuente: Actas Urológicas Españolas, 2021, ISSN 0210-4806

El Dr. Rubio es coautor de este artículo donde se evaluan nuevas técnicas para el tratamiento de cáncer de próstata que no afecta al músculo

Autores: J. Rubio-Briones, Ferrán Algaba, Enrique Gallardo, José Antonio Marcos-Rodríguez, Miguel Ángel Climent

Fuente: Cancers 2021, 13, 4762. https://doi.org/10.3390/cancers13194762

Horario de atención

Nuestras redes sociales

© 2021 Clínica de Urología y Andrología Dr. Rubio